These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 793267)

  • 21. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud's phenomenon.
    van der Meer J; Wouda AA; Kallenberg CG; Wesseling H
    Vasa Suppl; 1987; 18():71-5. PubMed ID: 3299819
    [No Abstract]   [Full Text] [Related]  

  • 24. Responses to nifedipine by patients with Raynaud's disease and Raynaud's phenomenon secondary to another disease.
    Riccio A; Del Puente A; Farinaro C; Scarpa R; Oriente P; Rocco P; Gioia M
    Clin Ther; 1987; 9(2):232-7. PubMed ID: 3568066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raynaud's phenomenon. Photoelectric plethysmography of the fingers of persons with and without Raynaud's phenomenon during cooling and warming up.
    Wouda AA
    Acta Med Scand; 1977; 201(6):519-23. PubMed ID: 878907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intra-arterial reserpine for Raynaud's syndrome. Systemic reactions without therapeutic benefit.
    Surwit RS; Gilgor RS; Duvic M; Allen LM; Neal JA
    Arch Dermatol; 1983 Sep; 119(9):733-5. PubMed ID: 6614959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
    Stoyneva Z
    Auton Neurosci; 2004 Nov; 116(1-2):62-8. PubMed ID: 15556839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Plethysmographic studies in Raynaud's phenomenon. Results of raubasin-ergotamine treatments].
    Neitzert A; Goebel KM
    Schweiz Med Wochenschr; 1974 Nov; 104(44):1595-6. PubMed ID: 4424617
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E; Virgilio S; Ghirardi R; Martinelli M
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of nifedipine (Adalat) on Raynaud's phenomenon].
    Baadsgaard O; Schmidt JF; Ironmann L
    Ugeskr Laeger; 1983 Dec; 145(49):3814-6. PubMed ID: 6364517
    [No Abstract]   [Full Text] [Related]  

  • 31. Phosphodiesterase inhibitors in Raynaud's phenomenon.
    Levien TL
    Ann Pharmacother; 2006; 40(7-8):1388-93. PubMed ID: 16835313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DIAS rounds. Nifedipine and prazosin in Raynaud's phenomenon.
    Pisenti L; Hart LL
    Drug Intell Clin Pharm; 1984 Mar; 18(3):213-4. PubMed ID: 6365494
    [No Abstract]   [Full Text] [Related]  

  • 33. Reactive hyperemia in Raynaud's disease.
    Pratesi F; Corsi C; Deidda C; Nuti A
    Biochem Exp Biol; 1977; 13(3):337-9. PubMed ID: 16296018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Slow release nifedipine in the treatment of Raynaud's phenomenon.
    Costantini A; Martelli E; Bavera P; Agus GB
    Int Angiol; 1987; 6(4):359-63. PubMed ID: 3330116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Raynaud's phenomenon.
    García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Pardo-Santos R; Levy R; Maldonado CG; Chávez GP; Cervera R
    Autoimmun Rev; 2008 Oct; 8(1):62-8. PubMed ID: 18692160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dihydroergocristine in the treatment of Raynaud's disease].
    Castelli PM; Sironi G
    Minerva Cardioangiol; 1977 Sep; 25(9):757-63. PubMed ID: 413069
    [No Abstract]   [Full Text] [Related]  

  • 37. Griseofulvin in Raynaud's phenomenon.
    Allen BR
    Lancet; 1971 Oct; 2(7729):840-1. PubMed ID: 4106870
    [No Abstract]   [Full Text] [Related]  

  • 38. A double-blind clinical trial of griseofulvin in patients with Raynaud's phenomenon.
    Sabri S; Higgins RF; Roberts VC; Cotton LT; Williams DI; Wilson LC
    Postgrad Med J; 1973 Sep; 49(575):641-3. PubMed ID: 4596620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tri-iodothyronine in Raynaud's phenomenon: further objective evidence of its beneficial effect.
    Dessein PH; Gledhill RF
    Br J Rheumatol; 1988 Jun; 27(3):244-6. PubMed ID: 3378131
    [No Abstract]   [Full Text] [Related]  

  • 40. Vasodilatation in the human hand; observations on primary Raynaud's disease and acrocyanosis of the upper extremities.
    PEACOCK JH
    Clin Sci; 1958 Nov; 17(4):575-86. PubMed ID: 13608967
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.